At Travere Therapeutics, we are in rare for life.

We come together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease.

Patients & Caregivers

Meet Lillie

On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies.

Pipeline

We continuously seek to understand the diverse perspectives of rare patients to courageously forge new paths that can make a difference in their lives and provide hope for today and tomorrow.

Patient Advocacy

Meet Paul

We are committed to broad access for our FDA-approved therapies, and we provide personalized clinical support services through the Total Care Hub.

OUR Therapies

Therapeutic Areas

These are the conditions for which we have an approved therapy or a research and development program.

Peroxisomal Biogenesis Disorder-Zellweger Spectrum Disorder (PBD-ZSD)

Cerebrotendinous Xanthomatosis (CTX)

Cystinuria

Bile Acid Synthesis Disorders (BASD)

Focal Segmental Glomerulosclerosis (FSGS)

IgA Nephropathy (IgAN)

Classical Homocystinuria (HCU)

Alagille Syndrome (ALGS)

N-Glycanase 1 (NGLY1) Deficiency

We are dedicated to staying informed and engaged on topics that may impact the rare disease community, featuring community members and sharing what we learn. Find info at our Pathfinder.

Travere Therapeutics Reports Second Quarter 2021 Financial Results

News

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2021 financial results and provided a corporate update.

Read the full press release >

July 29, 2021/by superadmin

Rare Revolution Magazine’s Releases Issue Focused on Diversity, Equity & Inclusion in Rare Disease

News

Rare Revolution Magazine Summer 2021 Cover

July 26, 2021 —

Today, Rare Revolution Magazine launched its summer issue dedicated to diversity, equity and inclusion in rare disease. The issue explores ways that rare disease patient advocacy organizations, individuals and industry are working to advance health equity. Articles include conversations with members of the rare community about race, gender, sexual identity, age bias, access to clinical trials and therapy. Travere is proud to collaborate with Rare Revolution Magazine on this issue.

Read the issue >

July 26, 2021/by superadmin

Stuart

IgAN, Rare Life

Ten years after being diagnosed with IgA nephropathy, a rare kidney disease, Stuart’s kidney function had depleted significantly. Today, after a lifesaving kidney donation from his wife, Stuart gives back to the kidney community through advocacy

July 25, 2021/by superadmin

In the News: Our president and CEO Eric Dube featured in Life Science Leader Magazine

News

July 1, 2021 — In its July issue published today, Life Science Leader Magazine featured our president and CEO Eric Dube. The feature piece, “How a First-Time CEO Transformed Retrophin Into Travere Therapeutics”, highlights Eric’s inspirational leadership journey, why Eric decided to join the company, his first 100 days as a new CEO, and the company’s transition from Retrophin to Travere Therapeutics.

Read the article >

July 1, 2021/by superadmin

Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

News

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 PROTECT Study. The pivotal PROTECT Study is evaluating the safety and efficacy of sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder that often progresses to end-stage kidney disease (ESKD). Topline efficacy data from the interim 36-week proteinuria endpoint analysis are expected in August 2021.

Read the full press release >

June 2, 2021/by superadmin

Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis

News

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today provided a regulatory update for its sparsentan program in focal segmental glomerulosclerosis (FSGS).

Read the full press release >

May 25, 2021/by superadmin

View More Pathfinder Stories